Literature DB >> 6170674

Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease.

A S Kadish, A T Doyle, E H Steinhauer, N A Ghossein.   

Abstract

Natural cytotoxicity was measured in 51 adult patients with solid epithelial malignant tumors and in 27 normal subjects. Peripheral blood leukocytes (PBL) from 31% of the patients and 7% of the controls failed to kill target cells (K562) in a short-term chromium-release assay. When patients were classified according to clinical stage, PBL from 12% of patients with localized cancers, but 50% of patients with advanced disease, failed to exhibit cytotoxicity within the normal range. Pretreatment of PBL with interferon alpha (IFN alpha) or with Newcastle Disease Virus (NDV), a potent inducer of IFN alpha, enhanced cytotoxicity from all normal subjects. Of patients whose PBL lacked spontaneous cytotoxicity, half were able to kill normally after pretreatment of PBL with IFN alpha or NDV. Virtually all the patients whose PBL were unable to kill despite pretreatment with IFN alpha or virus had disseminated malignancies. IFN alpha production by PBL exposed to NDV and to K562 cells was normal in all the patients regardless of stage of disease or ability to kill K562 cells. The observed defect in natural cytotoxicity is thus unlikely to be due to a failure of PBL to produce IFN alpha.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6170674

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Natural killer and antibody-dependent cellular cytotoxicity in cervical carcinoma patients.

Authors:  M N Satam; J N Suraiya; J J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Modulation by interferon alpha of the decreased natural killer activity in patients with glioblastoma.

Authors:  P Lapeña; C Isasi; J Vaquero; R Martinez; M Alvarez-Mon
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

Review 3.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Effect of recombinant gamma interferon on natural killer cell activity in patients with gastric cancer.

Authors:  Y Kuwahara; K Kusugami; K Morise; K Shimokata
Journal:  Gastroenterol Jpn       Date:  1987-08

5.  Reduced killer cell activity of lymphocytes from patients with asbestosis.

Authors:  M Kubota; S Kagamimori; K Yokoyama; A Okada
Journal:  Br J Ind Med       Date:  1985-04

6.  Interferon beta enhances the natural killer activity of patients with bladder carcinoma.

Authors:  L Moltó; J Carballido; L Manzano; C Olivier; P Lapeña; M Alvarez-Mon
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

7.  Particular features of cell-mediated immunity in patients with anaplastic gliomas. A comparison with kidney and bladder cancer patients.

Authors:  F Servadei; R Parente; M Bucci; E Beltrandi; F Tognetti; G Gaist
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2.

Authors:  R González-Amaro; J Alcocer-Varela; E Martínez-Cordero; D Alarcón-Segovia
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

9.  Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon.

Authors:  K Funa; G V Alm; L Rönnblom; K Oberg
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

10.  Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.

Authors:  W L Sibbitt; P M Mathews; A D Bankhurst
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.